- Trial phase
- Approved
- Time to market
- Already approved and commercialized (first FDA approval September 2021 for Alagille syndrome; PFIC label expansion July 2024; tablet formulation April 2025). A third label expansion for ultra-rare cholestatic liver diseases is expected to be filed with regulators in H1 2027.
- Why 4/10
- LIVMARLI is already approved and commercialized for Alagille Syndrome (2021) and PFIC (2024), with no pending PDUFA date. The next hard catalyst is a regulatory submission for label expansion into ultra-rare cholestatic liver diseases following the positive Phase 3 EXPAND readout, which Mirum guided would be part of five potential H1 2027 submissions. Since the drug is approved with no pending binary regulatory decision, the impactScore is capped at 5 per the rubric.
The next catalyst for LIVMARLI is a regulatory submission for label expansion into ultra-rare cholestatic liver diseases (including biliary atresia) following the positive Phase 3 EXPAND readout. Mirum guided for five potential regulatory submissions across its portfolio in H1 2027; a filing acceptance would be a positive signal. Watch for FDA submission announcements in early 2027.
Price Chart
Executive Summary
LIVMARLI (maralixibat) is an oral IBAT inhibitor approved for cholestatic pruritus in Alagille syndrome (2021) and PFIC (2024), and is the primary revenue driver for Mirum Pharmaceuticals (MIRM). The drug generated strong Q3 2026 sales that helped lift full-year guidance to $715-720M. In October 2026, the Phase 3 EXPAND study met its primary endpoint with highly significant results, positioning LIVMARLI for a potential third label expansion into ultra-rare cholestatic liver diseases including biliary atresia. Mirum expects to file regulatory submissions in H1 2027. Analyst consensus is strongly bullish with a mean price target of $154 (65% upside), though insider selling and some institutional trimming in Q3 temper the outlook. The stock trades at $93.99 as of November 13, 2026.
How It Works
LIVMARLI (maralixibat) is an oral liquid or tablet that blocks a protein called the ileal bile acid transporter (IBAT) in the gut. In rare liver diseases like Alagille syndrome and PFIC, bile acids build up to toxic levels because the liver cannot properly drain them. By blocking bile acid reabsorption in the intestine, LIVMARLI causes excess bile acids to be excreted in the stool instead of recirculating back to the liver, which reduces the severe itching (pruritus) and liver damage these patients experience.
Trial Status
LIVMARLI is approved in the US for cholestatic pruritus in Alagille syndrome (2021) and PFIC (2024), with a tablet formulation approved in 2025. It is also approved in the EU for PFIC and in Canada for ALGS and PFIC. The Phase 3 EXPAND study in ultra-rare cholestatic liver diseases (including biliary atresia) met its primary endpoint in October 2026 with statistically significant pruritus reduction (p=0.0004) and a 69% reduction in serum bile acids (p<0.0001). Mirum is preparing regulatory submissions for H1 2027.
The Two-Sided Case
Upcoming Catalysts
- Regulatory submission for LIVMARLI label expansion into ultra-rare cholestatic liver diseases (biliary atresia) expected H1 2027
- Potential FDA acceptance of supplemental NDA filing for EXPAND indication
- Continued commercial sales growth and potential cash flow positive milestone in 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Mirum Pharmaceuticals, Inc. CLUSTER MIRM ·Originating report